(E)-N'-benzylidene-2-phenylacetohydrazide | 4837-43-8

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: (E)-N'-benzylidene-2-phenylacetohydrazide
• 英文别名: trans-Phenylessigsaeure-2-benzyliden-hydrazid>；N'-benzylidene-2-phenylacetohydrazide；N-[(E)-benzylideneamino]-2-phenylacetamide
• CAS: 4837-43-8
• 化学式: C₁₅H₁₄N₂O
• 分子量: 238.289
• InChiKey: MPFFIYHRLWVBBJ-FOWTUZBSSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.8
• 重原子数：
  18
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.07
• 拓扑面积：
  41.5
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  (E)-N'-benzylidene-2-phenylacetohydrazide 、 lead(IV) acetate 以74%的产率得到
  参考文献：
  名称：

  STEPHANIDOU-STEPHANATOU, J.;LEFKOPOULOU, S., J. HETEROCYCL. CHEM., 1982, 19, N 4, 705-711

  摘要：

  DOI：
• 作为产物：
  描述：

  苯乙酸 在 硫酸 、 一水合肼 、 三氟乙酸 作用下， 以 甲醇 、 乙醇 为溶剂， 反应 2.0h， 生成 (E)-N'-benzylidene-2-phenylacetohydrazide
  参考文献：
  名称：

  Modulation of estrogen-related receptors subtype selectivity: Conversion of an ERRβ/γ selective agonist to ERRα/β/γ pan agonists

  摘要：

  Estrogen Related Receptors (ERRs) are key regulators of energy homeostasis and play important role in the etiology of metabolic disorders, skeletal muscle related disorders, and neurodegenerative diseases. Among the three ERR isoforms, ERR alpha emerged as a potential drug target for metabolic and neurodegenerative diseases. Although ERR beta/gamma selective agonist chemical tools have been identified, there are no chemical tools that effectively target ERR alpha agonism. We successfully engineered high affinity ERR alpha agonism into a chemical scaffold that displays selective ERR beta/gamma agonist activity (GSK4716), providing novel ERR alpha/beta/gamma pan agonists that can be used as tools to probe the physiological roles of these nuclear receptors. We identified the structural requirements to enhance selectivity toward ERR alpha. Molecular modeling shows that our novel modulators have favorable binding modes in the LBP of ERR alpha and can induce conformational changes where Phe328 that originally occupies the pocket is dislocated to accommodate the ligands in a rather small cavity. The best agonists up-regulated the expression of target genes PGC-1 alpha and PGC-1 beta, which are necessary to achieve maximal mitochondrial biogenesis. Moreover, they increased the mRNA levels of PDK4, which play an important role in energy homeostasis.

  DOI：

  10.1016/j.bioorg.2020.104079

文献信息

• PDE10 INHIBITORS AND RELATED COMPOSITIONS AND METHODS
  申请人：Cutshall Neil S.

  公开号：US20100035872A1

  公开（公告）日：2010-02-11

  Compounds that inhibit PDE10 are disclosed that have utility in the treatment of a variety of conditions, including (but not limited to) psychotic, anxiety, movement disorders and/or neurological disorders such as Parkinson's disease, Huntington's disease, Alzheimer's disease, encephalitis, phobias, epilepsy, aphasia, Bell's palsy, cerebral palsy, sleep disorders, pain, Tourette's syndrome, schizophrenia, delusional disorders, drug-induced psychosis and panic and obsessive-compulsive disorders. Pharmaceutically acceptable salts, stereoisomers, solvates and prodrugs of the compounds are also provided. Also disclosed are compositions containing a compound in combination with a pharmaceutically acceptable carrier, as well as methods relating to the use thereof for inhibiting PDE10 in a warm-blooded animal in need of the same.

  揭示了抑制PDE10的化合物，可用于治疗多种疾病，包括（但不限于）精神病、焦虑、运动障碍和/或神经系统疾病，如帕金森病、亨廷顿病、阿尔茨海默病、脑炎、恐惧症、癫痫、失语症、贝尔氏面瘫、脑性瘫痪、睡眠障碍、疼痛、抽动症、精神分裂症、妄想症、药物诱导的精神病和惊恐症以及强迫症。此外，还提供了这些化合物的药用盐、立体异构体、溶剂合物和前药。还揭示了含有化合物的组合物，与药用载体结合，以及与使用这些组合物抑制温血动物中的PDE10相关的方法。
• SHAH, S. J.;SHAH, S. R.;DESAI, N. C.;THAKER, K. A., J. INDIAN CHEM. SOC., 1984, 61, N 7, 648-649
  作者：SHAH, S. J.、SHAH, S. R.、DESAI, N. C.、THAKER, K. A.

  DOI：——

  日期：——
• AL-FARKH YOUSUF A.; AL-HAJJAR FAROUK H.; HAMOND HAYAT S., J. CHEM. AND ENG. DATA, 1978, 23, NO 4, 345-349
  作者：AL-FARKH YOUSUF A.、 AL-HAJJAR FAROUK H.、 HAMOND HAYAT S.

  DOI：——

  日期：——
• US8377930B2
  申请人：——

  公开号：US8377930B2

  公开（公告）日：2013-02-19
• US9783521B2
  申请人：——

  公开号：US9783521B2

  公开（公告）日：2017-10-10